Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
LIVONIA, Mich., Oct. 26, 2016 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH (nonalcoholic fatty liver disease), today announced that it will issue a press release announcing financial results for the third quarter ended September 30, 2016 on Wednesday, November 2.
The Company also announced that Mina Sooch, Gemphire’s CEO, will be presenting at the 25th Annual Credit Suisse 2016 Healthcare Conference, being held at the Phoenician Hotel in Scottsdale, Arizona, November 7-8.
| 25th Annual Credit Suisse Healthcare Conference Presentation Details: | |
| Date: | Monday, November 7 |
| Time: | 10:00am Mountain Time/12:00pm Eastern Time |
| Location: | Phoenician Hotel, Ballroom G |
The presentation slides will be available immediately prior to and for 90 days following the presentation on the Investors and Media page of Gemphire’s website at http://ir.gemphire.com.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease). Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics (734)-245-1700
